Identify Which Patients May Benefit From Evusheld

You'll hear buzz about Evusheld (tixagevimab/cilgavimab), the first PRE-exposure prophylaxis med for COVID-19, for patients age 12 and up.

It's a COVID-19 monoclonal antibody ("MAb")...similar to sotrovimab, casirivimab/imdevimab, etc.

Other COVID-19 mabs are IV infusions for TREATMENT...Evusheld is an IM injection for PREVENTION. It has a longer half-life than most mabs...about 90 days after a single dose.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote